CN111487417A - Mcr-1耐药蛋白双抗夹心elisa检测试剂盒及检测方法 - Google Patents
Mcr-1耐药蛋白双抗夹心elisa检测试剂盒及检测方法 Download PDFInfo
- Publication number
- CN111487417A CN111487417A CN202010542174.6A CN202010542174A CN111487417A CN 111487417 A CN111487417 A CN 111487417A CN 202010542174 A CN202010542174 A CN 202010542174A CN 111487417 A CN111487417 A CN 111487417A
- Authority
- CN
- China
- Prior art keywords
- solution
- antibody
- mcr
- detection
- hrp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 64
- 101150004219 MCR1 gene Proteins 0.000 title claims abstract description 61
- 239000003814 drug Substances 0.000 title claims abstract description 23
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 23
- 229940079593 drug Drugs 0.000 title claims abstract description 22
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 19
- 238000002965 ELISA Methods 0.000 claims abstract description 8
- 241000894006 Bacteria Species 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims description 69
- 238000000034 method Methods 0.000 claims description 17
- 239000011248 coating agent Substances 0.000 claims description 16
- 238000000576 coating method Methods 0.000 claims description 16
- 108090000790 Enzymes Proteins 0.000 claims description 13
- 102000004190 Enzymes Human genes 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 13
- 238000005406 washing Methods 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 12
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 9
- 239000007853 buffer solution Substances 0.000 claims description 9
- 230000003053 immunization Effects 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 9
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 claims description 8
- 238000007865 diluting Methods 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 8
- 239000002244 precipitate Substances 0.000 claims description 8
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 7
- 238000003752 polymerase chain reaction Methods 0.000 claims description 7
- 238000007789 sealing Methods 0.000 claims description 7
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 6
- 230000000903 blocking effect Effects 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 6
- 239000012089 stop solution Substances 0.000 claims description 6
- 239000000758 substrate Substances 0.000 claims description 6
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 5
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 claims description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 229960002303 citric acid monohydrate Drugs 0.000 claims description 4
- 238000010367 cloning Methods 0.000 claims description 4
- 238000000502 dialysis Methods 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000007974 sodium acetate buffer Substances 0.000 claims description 4
- 241001522878 Escherichia coli B Species 0.000 claims description 3
- 241000872931 Myoporum sandwicense Species 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- 239000013604 expression vector Substances 0.000 claims description 3
- 239000006166 lysate Substances 0.000 claims description 3
- 239000011259 mixed solution Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 239000012224 working solution Substances 0.000 claims description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 2
- 230000009471 action Effects 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 238000001042 affinity chromatography Methods 0.000 claims description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 2
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- YHEPZZFDBQOSSN-UHFFFAOYSA-N bis(1,2,2,6,6-pentamethylpiperidin-4-yl) decanedioate;1-o-methyl 10-o-(1,2,2,6,6-pentamethylpiperidin-4-yl) decanedioate Chemical compound COC(=O)CCCCCCCCC(=O)OC1CC(C)(C)N(C)C(C)(C)C1.C1C(C)(C)N(C)C(C)(C)CC1OC(=O)CCCCCCCCC(=O)OC1CC(C)(C)N(C)C(C)(C)C1 YHEPZZFDBQOSSN-UHFFFAOYSA-N 0.000 claims description 2
- 229940078916 carbamide peroxide Drugs 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- 238000004587 chromatography analysis Methods 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- DGLRDKLJZLEJCY-UHFFFAOYSA-L disodium hydrogenphosphate dodecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O DGLRDKLJZLEJCY-UHFFFAOYSA-L 0.000 claims description 2
- 239000013613 expression plasmid Substances 0.000 claims description 2
- 239000002808 molecular sieve Substances 0.000 claims description 2
- WHQSYGRFZMUQGQ-UHFFFAOYSA-N n,n-dimethylformamide;hydrate Chemical compound O.CN(C)C=O WHQSYGRFZMUQGQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 2
- 239000000047 product Substances 0.000 claims description 2
- 238000003259 recombinant expression Methods 0.000 claims description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 claims description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 claims description 2
- 230000001131 transforming effect Effects 0.000 claims description 2
- AQLJVWUFPCUVLO-UHFFFAOYSA-N urea hydrogen peroxide Chemical compound OO.NC(N)=O AQLJVWUFPCUVLO-UHFFFAOYSA-N 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 230000001580 bacterial effect Effects 0.000 claims 2
- 239000013592 cell lysate Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000527 sonication Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 2
- 150000001413 amino acids Chemical group 0.000 description 9
- 241000588747 Klebsiella pneumoniae Species 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 7
- 241000607768 Shigella Species 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 6
- 206010003445 Ascites Diseases 0.000 description 5
- 108010078777 Colistin Proteins 0.000 description 5
- 229960003346 colistin Drugs 0.000 description 5
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 5
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 5
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 108010050848 glycylleucine Proteins 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
- 108010051242 phenylalanylserine Proteins 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 3
- BYYNJRSNDARRBX-YFKPBYRVSA-N Gly-Gln-Gly Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O BYYNJRSNDARRBX-YFKPBYRVSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 101100344651 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) mcr-1 gene Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108010089804 glycyl-threonine Proteins 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- IOFVWPYSRSCWHI-JXUBOQSCSA-N Ala-Thr-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)N IOFVWPYSRSCWHI-JXUBOQSCSA-N 0.000 description 2
- XVAPVJNJGLWGCS-ACZMJKKPSA-N Asn-Glu-Asn Chemical compound C(CC(=O)O)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N XVAPVJNJGLWGCS-ACZMJKKPSA-N 0.000 description 2
- DXVMJJNAOVECBA-WHFBIAKZSA-N Asn-Gly-Asn Chemical compound NC(=O)C[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O DXVMJJNAOVECBA-WHFBIAKZSA-N 0.000 description 2
- GMUOCGCDOYYWPD-FXQIFTODSA-N Asn-Pro-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O GMUOCGCDOYYWPD-FXQIFTODSA-N 0.000 description 2
- MRQQMVZUHXUPEV-IHRRRGAJSA-N Asp-Arg-Phe Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O MRQQMVZUHXUPEV-IHRRRGAJSA-N 0.000 description 2
- NYQHSUGFEWDWPD-ACZMJKKPSA-N Asp-Gln-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)O)N NYQHSUGFEWDWPD-ACZMJKKPSA-N 0.000 description 2
- 241001360526 Escherichia coli ATCC 25922 Species 0.000 description 2
- 241000327731 Escherichia coli ATCC 35150 Species 0.000 description 2
- XOKGKOQWADCLFQ-GARJFASQSA-N Gln-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)N)N)C(=O)O XOKGKOQWADCLFQ-GARJFASQSA-N 0.000 description 2
- YPMDZWPZFOZYFG-GUBZILKMSA-N Gln-Leu-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YPMDZWPZFOZYFG-GUBZILKMSA-N 0.000 description 2
- ZFBBMCKQSNJZSN-AUTRQRHGSA-N Gln-Val-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O ZFBBMCKQSNJZSN-AUTRQRHGSA-N 0.000 description 2
- WZZSKAJIHTUUSG-ACZMJKKPSA-N Glu-Ala-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O WZZSKAJIHTUUSG-ACZMJKKPSA-N 0.000 description 2
- STVHDEHTKFXBJQ-LAEOZQHASA-N Gly-Glu-Ile Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O STVHDEHTKFXBJQ-LAEOZQHASA-N 0.000 description 2
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 2
- GBYYQVBXFVDJPJ-WLTAIBSBSA-N Gly-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)CN)O GBYYQVBXFVDJPJ-WLTAIBSBSA-N 0.000 description 2
- FOCSWPCHUDVNLP-PMVMPFDFSA-N His-Trp-Tyr Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)NC(=O)[C@H](CC4=CN=CN4)N FOCSWPCHUDVNLP-PMVMPFDFSA-N 0.000 description 2
- ZTLGVASZOIKNIX-DCAQKATOSA-N Leu-Gln-Glu Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N ZTLGVASZOIKNIX-DCAQKATOSA-N 0.000 description 2
- FEHQLKKBVJHSEC-SZMVWBNQSA-N Leu-Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 FEHQLKKBVJHSEC-SZMVWBNQSA-N 0.000 description 2
- KIZIOFNVSOSKJI-CIUDSAMLSA-N Leu-Ser-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N KIZIOFNVSOSKJI-CIUDSAMLSA-N 0.000 description 2
- LCNASHSOFMRYFO-WDCWCFNPSA-N Leu-Thr-Gln Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O LCNASHSOFMRYFO-WDCWCFNPSA-N 0.000 description 2
- UWKNTTJNVSYXPC-CIUDSAMLSA-N Lys-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN UWKNTTJNVSYXPC-CIUDSAMLSA-N 0.000 description 2
- ZUGVARDEGWMMLK-SRVKXCTJSA-N Lys-Ser-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN ZUGVARDEGWMMLK-SRVKXCTJSA-N 0.000 description 2
- GILLQRYAWOMHED-DCAQKATOSA-N Lys-Val-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN GILLQRYAWOMHED-DCAQKATOSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- GNRMAQSIROFNMI-IXOXFDKPSA-N Phe-Thr-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O GNRMAQSIROFNMI-IXOXFDKPSA-N 0.000 description 2
- JMVQDLDPDBXAAX-YUMQZZPRSA-N Pro-Gly-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 JMVQDLDPDBXAAX-YUMQZZPRSA-N 0.000 description 2
- QKQDTEYDEIJPNK-GUBZILKMSA-N Ser-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO QKQDTEYDEIJPNK-GUBZILKMSA-N 0.000 description 2
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 2
- XXXAXOWMBOKTRN-XPUUQOCRSA-N Ser-Gly-Val Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O XXXAXOWMBOKTRN-XPUUQOCRSA-N 0.000 description 2
- KCGIREHVWRXNDH-GARJFASQSA-N Ser-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N KCGIREHVWRXNDH-GARJFASQSA-N 0.000 description 2
- JVTHIXKSVYEWNI-JRQIVUDYSA-N Thr-Asn-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O JVTHIXKSVYEWNI-JRQIVUDYSA-N 0.000 description 2
- KRPKYGOFYUNIGM-XVSYOHENSA-N Thr-Asp-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N)O KRPKYGOFYUNIGM-XVSYOHENSA-N 0.000 description 2
- MECLEFZMPPOEAC-VOAKCMCISA-N Thr-Leu-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N)O MECLEFZMPPOEAC-VOAKCMCISA-N 0.000 description 2
- DEGCBBCMYWNJNA-RHYQMDGZSA-N Thr-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)[C@@H](C)O DEGCBBCMYWNJNA-RHYQMDGZSA-N 0.000 description 2
- JAWUQFCGNVEDRN-MEYUZBJRSA-N Thr-Tyr-Leu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)O)N)O JAWUQFCGNVEDRN-MEYUZBJRSA-N 0.000 description 2
- FYBFTPLPAXZBOY-KKHAAJSZSA-N Thr-Val-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O FYBFTPLPAXZBOY-KKHAAJSZSA-N 0.000 description 2
- KCZGSXPFPNKGLE-WDSOQIARSA-N Trp-Met-His Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)N KCZGSXPFPNKGLE-WDSOQIARSA-N 0.000 description 2
- UOXPLPBMEPLZBW-WDSOQIARSA-N Trp-Val-Lys Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(O)=O)=CNC2=C1 UOXPLPBMEPLZBW-WDSOQIARSA-N 0.000 description 2
- 108010064997 VPY tripeptide Proteins 0.000 description 2
- VHIZXDZMTDVFGX-DCAQKATOSA-N Val-Ser-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N VHIZXDZMTDVFGX-DCAQKATOSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 108010092854 aspartyllysine Proteins 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 108010009962 valyltyrosine Proteins 0.000 description 2
- WYPUMLRSQMKIJU-BPNCWPANSA-N Ala-Arg-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O WYPUMLRSQMKIJU-BPNCWPANSA-N 0.000 description 1
- OZNSCVPYWZRQPY-CIUDSAMLSA-N Arg-Asp-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O OZNSCVPYWZRQPY-CIUDSAMLSA-N 0.000 description 1
- PNIGSVZJNVUVJA-BQBZGAKWSA-N Arg-Gly-Asn Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O PNIGSVZJNVUVJA-BQBZGAKWSA-N 0.000 description 1
- HUZGPXBILPMCHM-IHRRRGAJSA-N Asn-Arg-Phe Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O HUZGPXBILPMCHM-IHRRRGAJSA-N 0.000 description 1
- DDPXDCKYWDGZAL-BQBZGAKWSA-N Asn-Gly-Arg Chemical compound NC(=O)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N DDPXDCKYWDGZAL-BQBZGAKWSA-N 0.000 description 1
- ORJQQZIXTOYGGH-SRVKXCTJSA-N Asn-Lys-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O ORJQQZIXTOYGGH-SRVKXCTJSA-N 0.000 description 1
- VZNOVQKGJQJOCS-SRVKXCTJSA-N Asp-Asp-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O VZNOVQKGJQJOCS-SRVKXCTJSA-N 0.000 description 1
- YBMUFUWSMIKJQA-GUBZILKMSA-N Asp-Gln-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)O)N YBMUFUWSMIKJQA-GUBZILKMSA-N 0.000 description 1
- HOBNTSHITVVNBN-ZPFDUUQYSA-N Asp-Ile-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC(=O)O)N HOBNTSHITVVNBN-ZPFDUUQYSA-N 0.000 description 1
- MYOHQBFRJQFIDZ-KKUMJFAQSA-N Asp-Leu-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O MYOHQBFRJQFIDZ-KKUMJFAQSA-N 0.000 description 1
- WMLFFCRUSPNENW-ZLUOBGJFSA-N Asp-Ser-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O WMLFFCRUSPNENW-ZLUOBGJFSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- GEEXORWTBTUOHC-FXQIFTODSA-N Cys-Arg-Ser Chemical compound C(C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CS)N)CN=C(N)N GEEXORWTBTUOHC-FXQIFTODSA-N 0.000 description 1
- IZUNQDRIAOLWCN-YUMQZZPRSA-N Cys-Leu-Gly Chemical compound CC(C)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CS)N IZUNQDRIAOLWCN-YUMQZZPRSA-N 0.000 description 1
- NYCVMJGIJYQWDO-CIUDSAMLSA-N Gln-Ser-Arg Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O NYCVMJGIJYQWDO-CIUDSAMLSA-N 0.000 description 1
- QZQYITIKPAUDGN-GVXVVHGQSA-N Gln-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCC(=O)N)N QZQYITIKPAUDGN-GVXVVHGQSA-N 0.000 description 1
- PVBBEKPHARMPHX-DCAQKATOSA-N Glu-Gln-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCC(O)=O PVBBEKPHARMPHX-DCAQKATOSA-N 0.000 description 1
- GJBUAAAIZSRCDC-GVXVVHGQSA-N Glu-Leu-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O GJBUAAAIZSRCDC-GVXVVHGQSA-N 0.000 description 1
- SJJHXJDSNQJMMW-SRVKXCTJSA-N Glu-Lys-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O SJJHXJDSNQJMMW-SRVKXCTJSA-N 0.000 description 1
- UQJNXZSSGQIPIQ-FBCQKBJTSA-N Gly-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)CN UQJNXZSSGQIPIQ-FBCQKBJTSA-N 0.000 description 1
- JBJNKUOMNZGQIM-PYJNHQTQSA-N His-Arg-Ile Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JBJNKUOMNZGQIM-PYJNHQTQSA-N 0.000 description 1
- SDTPKSOWFXBACN-GUBZILKMSA-N His-Glu-Asp Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O SDTPKSOWFXBACN-GUBZILKMSA-N 0.000 description 1
- FBOMZVOKCZMDIG-XQQFMLRXSA-N His-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CN=CN2)N FBOMZVOKCZMDIG-XQQFMLRXSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- RGSOCXHDOPQREB-ZPFDUUQYSA-N Ile-Asp-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)O)N RGSOCXHDOPQREB-ZPFDUUQYSA-N 0.000 description 1
- NZGTYCMLUGYMCV-XUXIUFHCSA-N Ile-Lys-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N NZGTYCMLUGYMCV-XUXIUFHCSA-N 0.000 description 1
- KAFOIVJDVSZUMD-DCAQKATOSA-N Leu-Gln-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O KAFOIVJDVSZUMD-DCAQKATOSA-N 0.000 description 1
- KAFOIVJDVSZUMD-UHFFFAOYSA-N Leu-Gln-Gln Natural products CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)NC(CCC(N)=O)C(O)=O KAFOIVJDVSZUMD-UHFFFAOYSA-N 0.000 description 1
- POZULHZYLPGXMR-ONGXEEELSA-N Leu-Gly-Val Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O POZULHZYLPGXMR-ONGXEEELSA-N 0.000 description 1
- NRFGTHFONZYFNY-MGHWNKPDSA-N Leu-Ile-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NRFGTHFONZYFNY-MGHWNKPDSA-N 0.000 description 1
- CHJKEDSZNSONPS-DCAQKATOSA-N Leu-Pro-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O CHJKEDSZNSONPS-DCAQKATOSA-N 0.000 description 1
- UFPLDOKWDNTTRP-ULQDDVLXSA-N Leu-Tyr-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)CC1=CC=C(O)C=C1 UFPLDOKWDNTTRP-ULQDDVLXSA-N 0.000 description 1
- YQFZRHYZLARWDY-IHRRRGAJSA-N Leu-Val-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN YQFZRHYZLARWDY-IHRRRGAJSA-N 0.000 description 1
- VEGLGAOVLFODGC-GUBZILKMSA-N Lys-Glu-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O VEGLGAOVLFODGC-GUBZILKMSA-N 0.000 description 1
- SKRGVGLIRUGANF-AVGNSLFASA-N Lys-Leu-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O SKRGVGLIRUGANF-AVGNSLFASA-N 0.000 description 1
- PDIDTSZKKFEDMB-UWVGGRQHSA-N Lys-Pro-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O PDIDTSZKKFEDMB-UWVGGRQHSA-N 0.000 description 1
- DIBZLYZXTSVGLN-CIUDSAMLSA-N Lys-Ser-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O DIBZLYZXTSVGLN-CIUDSAMLSA-N 0.000 description 1
- RMLLCGYYVZKKRT-CIUDSAMLSA-N Met-Ser-Glu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O RMLLCGYYVZKKRT-CIUDSAMLSA-N 0.000 description 1
- 108010047562 NGR peptide Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- CLNJSLSHKJECME-BQBZGAKWSA-N Pro-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]1CCCN1 CLNJSLSHKJECME-BQBZGAKWSA-N 0.000 description 1
- SOACYAXADBWDDT-CYDGBPFRSA-N Pro-Ile-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SOACYAXADBWDDT-CYDGBPFRSA-N 0.000 description 1
- RMODQFBNDDENCP-IHRRRGAJSA-N Pro-Lys-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O RMODQFBNDDENCP-IHRRRGAJSA-N 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- HBZBPFLJNDXRAY-FXQIFTODSA-N Ser-Ala-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O HBZBPFLJNDXRAY-FXQIFTODSA-N 0.000 description 1
- GXXTUIUYTWGPMV-FXQIFTODSA-N Ser-Arg-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O GXXTUIUYTWGPMV-FXQIFTODSA-N 0.000 description 1
- VQBLHWSPVYYZTB-DCAQKATOSA-N Ser-Arg-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)N VQBLHWSPVYYZTB-DCAQKATOSA-N 0.000 description 1
- HBOABDXGTMMDSE-GUBZILKMSA-N Ser-Arg-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O HBOABDXGTMMDSE-GUBZILKMSA-N 0.000 description 1
- BLPYXIXXCFVIIF-FXQIFTODSA-N Ser-Cys-Arg Chemical compound C(C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CO)N)CN=C(N)N BLPYXIXXCFVIIF-FXQIFTODSA-N 0.000 description 1
- FMDHKPRACUXATF-ACZMJKKPSA-N Ser-Gln-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O FMDHKPRACUXATF-ACZMJKKPSA-N 0.000 description 1
- UIPXCLNLUUAMJU-JBDRJPRFSA-N Ser-Ile-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O UIPXCLNLUUAMJU-JBDRJPRFSA-N 0.000 description 1
- MUJQWSAWLLRJCE-KATARQTJSA-N Ser-Leu-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MUJQWSAWLLRJCE-KATARQTJSA-N 0.000 description 1
- JWOBLHJRDADHLN-KKUMJFAQSA-N Ser-Leu-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O JWOBLHJRDADHLN-KKUMJFAQSA-N 0.000 description 1
- IXZHZUGGKLRHJD-DCAQKATOSA-N Ser-Leu-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O IXZHZUGGKLRHJD-DCAQKATOSA-N 0.000 description 1
- HHJFMHQYEAAOBM-ZLUOBGJFSA-N Ser-Ser-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O HHJFMHQYEAAOBM-ZLUOBGJFSA-N 0.000 description 1
- PPCZVWHJWJFTFN-ZLUOBGJFSA-N Ser-Ser-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O PPCZVWHJWJFTFN-ZLUOBGJFSA-N 0.000 description 1
- FZXOPYUEQGDGMS-ACZMJKKPSA-N Ser-Ser-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O FZXOPYUEQGDGMS-ACZMJKKPSA-N 0.000 description 1
- SIEBDTCABMZCLF-XGEHTFHBSA-N Ser-Val-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SIEBDTCABMZCLF-XGEHTFHBSA-N 0.000 description 1
- CAJFZCICSVBOJK-SHGPDSBTSA-N Thr-Ala-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CAJFZCICSVBOJK-SHGPDSBTSA-N 0.000 description 1
- SPVHQURZJCUDQC-VOAKCMCISA-N Thr-Lys-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O SPVHQURZJCUDQC-VOAKCMCISA-N 0.000 description 1
- ABWNZPOIUJMNKT-IXOXFDKPSA-N Thr-Phe-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O ABWNZPOIUJMNKT-IXOXFDKPSA-N 0.000 description 1
- WPSKTVVMQCXPRO-BWBBJGPYSA-N Thr-Ser-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WPSKTVVMQCXPRO-BWBBJGPYSA-N 0.000 description 1
- IEZVHOULSUULHD-XGEHTFHBSA-N Thr-Ser-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O IEZVHOULSUULHD-XGEHTFHBSA-N 0.000 description 1
- MNYNCKZAEIAONY-XGEHTFHBSA-N Thr-Val-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O MNYNCKZAEIAONY-XGEHTFHBSA-N 0.000 description 1
- SVGAWGVHFIYAEE-JSGCOSHPSA-N Trp-Gly-Gln Chemical compound C1=CC=C2C(C[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)=CNC2=C1 SVGAWGVHFIYAEE-JSGCOSHPSA-N 0.000 description 1
- WDGDKHLSDIOXQC-ACRUOGEOSA-N Tyr-Leu-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 WDGDKHLSDIOXQC-ACRUOGEOSA-N 0.000 description 1
- NSGZILIDHCIZAM-KKUMJFAQSA-N Tyr-Leu-Ser Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N NSGZILIDHCIZAM-KKUMJFAQSA-N 0.000 description 1
- UPODKYBYUBTWSV-BZSNNMDCSA-N Tyr-Phe-Cys Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CS)C(O)=O)C1=CC=C(O)C=C1 UPODKYBYUBTWSV-BZSNNMDCSA-N 0.000 description 1
- LDKDSFQSEUOCOO-RPTUDFQQSA-N Tyr-Thr-Phe Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O LDKDSFQSEUOCOO-RPTUDFQQSA-N 0.000 description 1
- ANHVRCNNGJMJNG-BZSNNMDCSA-N Tyr-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CS)C(=O)O)N)O ANHVRCNNGJMJNG-BZSNNMDCSA-N 0.000 description 1
- FZADUTOCSFDBRV-RNXOBYDBSA-N Tyr-Tyr-Trp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CC=C(O)C=C1 FZADUTOCSFDBRV-RNXOBYDBSA-N 0.000 description 1
- QWCZXKIFPWPQHR-JYJNAYRXSA-N Val-Pro-Tyr Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 QWCZXKIFPWPQHR-JYJNAYRXSA-N 0.000 description 1
- PZTZYZUTCPZWJH-FXQIFTODSA-N Val-Ser-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PZTZYZUTCPZWJH-FXQIFTODSA-N 0.000 description 1
- PGBMPFKFKXYROZ-UFYCRDLUSA-N Val-Tyr-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)O)N PGBMPFKFKXYROZ-UFYCRDLUSA-N 0.000 description 1
- OWFGFHQMSBTKLX-UFYCRDLUSA-N Val-Tyr-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N OWFGFHQMSBTKLX-UFYCRDLUSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 108010081404 acein-2 Proteins 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 108010084758 arginyl-tyrosyl-aspartic acid Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 108010078144 glutaminyl-glycine Proteins 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 108010034529 leucyl-lysine Proteins 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 108010070409 phenylalanyl-glycyl-glycine Proteins 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000009008 sandwich enzyme-linked immunosorbent assay kity Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 108010038745 tryptophylglycine Proteins 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
本发明提供一种用于检测细菌中MCR‑1耐药蛋白的双抗夹心ELISA检测试剂盒及其检测方法，包括包被有单克隆抗体4E5的酶标板、检测抗体5B3‑HRP、MCR‑1蛋白标准品。本发明选用4E5作为捕获抗体，5B3‑HRP作为检测抗体研制了MCR‑1双抗夹心ELISA检测试剂盒，并对其进行了方法学系统评估，结果显示试剂盒特异性好，灵敏度高，为MCR‑1阳性耐药菌的快速检测提供了一种技术手段。
Description
技术领域
本发明涉及一种用于检测MCR-1耐药蛋白的双抗夹心ELISA检测试剂盒及方法，属于免疫学分析技术领域。
背景技术
近年来，由于多重耐药菌株的出现，粘菌素在人类医学中被重新引入，以治疗与健康相关的感染，从而导致大肠埃希菌和沙门菌对黏菌素的耐药日趋严重。2015年，华南农业大学药理课题组于上海一猪场首次发现一株质粒介导的可转移耐药基因MCR-1，且报道在人和动物和食物中均检测出质粒介导的粘菌素耐药基因MCR-1，并证实该基因可通过接合型质粒在不同菌属间传播，且速度快。这与之前大家所认知的染色体介导粘菌素耐药所不同，从分子机制上解释了目前国内外多粘菌素耐药性迅速升高的原因。MCR-1基因的发现，预示着抗生素的最后一道防线---多粘菌素已然遭到威胁，同时对动物和人类的健康也造成了严重的威胁。
目前，现有的耐药基因检测方法中，一般通过传统的微生物培养法、药敏试验法、聚合酶链反应（PCR）技术、基因芯片技术等方法来判定微生物是否对某一种抗生素具有耐药性，但前两种方法费时且操作复杂，不能满足现场检测的需求。而后两种检测方法操作繁琐，需要专业仪器且昂贵等缺点，不适合临床大规模推广应用。本发明应用的酶联免疫吸附法（ELISA）具有快速、灵敏、特异性好且操作简便等特点，因此建立一种用于检测MCR-1基因的双抗夹心ELISA检测试剂盒及方法，对其基因检测和方法开发具有重要意义。
发明内容
在本发明的目的是提供一种灵敏度高、特异性强、操作简便、检测快速的检测MCR-1耐药蛋白的双抗夹心酶联免疫试剂盒及检测方法。
为了实现上述目的，本发明采用的技术方案是：
一种用于检测细菌中MCR-1耐药蛋白的双抗夹心ELISA检测试剂盒，包括：包被有单克隆抗体4E5的酶标板、检测抗体5B3-HRP、MCR-1蛋白标准品。
在一个实施方案中，所述检测MCR-1耐药蛋白的双抗夹心ELISA检测试剂盒，包括：
PCR扩增目的片段并克隆至表达载体pET28a，将成功构建的重组表达质粒转化至大肠杆菌BL21（DE3）中，IPTG诱导表达，经亲和层析和分子筛层析高度纯化后得到MCR-1重组蛋白；
上述重组MCR-1蛋白氨基酸序列为序列1。
在一个实施方案中，所述MCR-1单克隆抗体4E5，5B3为采用重组MCR-1蛋白免疫小鼠，经融合、克隆、筛选，得到的；
所述单克隆抗体4E5的重链可变区的氨基酸序列为序列2；
所述单克隆抗体4E5的轻链可变区的氨基酸序列为序列3；
所述单克隆抗体5B3的重链可变区的氨基酸序列为序列4；
所述单克隆抗体5B3的轻链可变区的氨基酸序列为序列5。
在一个实施方案中，所述检测抗体5B3-HRP的制备方法包括如下步骤：
（1）称取5 mg HRP溶于1mL三蒸水中，逐滴缓慢加入0.20 mL新配的0.1 M NaIO4溶液，4℃避光搅拌25 min，活化HRP，颜色由棕色变为绿色；上述溶液装入透析袋中，用1 M，pH 4.4的醋酸钠缓冲液中4℃过夜透析，然后10000 r/min，4℃，离心10 min，去除沉淀；得到透析后的HRP；
（2）将单克隆抗体5B3用0.2 M，pH为9.5的碳酸缓冲液4℃透析过夜，得到透析后的抗体；
（3）将透析后的HRP加入0.16 M乙二醇（每mg酶加0.1 mL），4℃避光搅拌1 h，然后加入透析后的抗体；两者混匀后用0.05 M，pH为9.5的碳酸缓冲液4℃透析过夜，得到HRP-抗体混合液；
（4）对0.15 M pH 7.4 PBS透析过夜；搅拌下逐滴加入等体积饱和硫酸氨，4℃避光搅拌3 h；4℃，10000 rpm离心15 min，弃上清；PBS溶解沉淀，得到经辣根过氧化物酶标记的检测抗体HRP-5B3。
在一个实施方案中，所述检测细菌中MCR-1耐药蛋白的双抗夹心ELISA检测试剂盒，还包括如下步骤：
1）包被有单克隆抗体4E5的酶标板的制备：将单克隆抗体4E5用碳酸盐缓冲液稀释成浓度为5 μg/mL的抗体包被液，每孔100 μL，4℃包被过夜后洗板；然后每孔加入100 μL封闭液，37℃、湿度30-40%封闭2 h，37℃、湿度30-40%恒温干燥2 h；
2）检测抗体稀释液：0.01 M pH7.4的PBST溶液；
3）检测抗体工作液的制备：检测抗体5B3-HRP按照1:30000比例稀释后备用；
4）样品稀释液的制备：0.01 M pH7.4的PBS溶液；
5）底物A液的制备：含0.08%过氧化脲、0.025%PEG-2000、3.58%十二水合磷酸氢二钠、0.96%一水合柠檬酸水溶液，调pH值至7.4；
6）底物B液的制备：含1.03%一水合柠檬酸、0.04% TMB、0.0008%硫代硫酸钠、0.1%光稳定剂292、3% DMF水溶液，调pH值至5.0。
本发明的第二个目的在于提供一种MCR-1蛋白双抗夹心ELISA检测方法，该方法操作简便，检测快速，特异性强，灵敏度高。
具体的说，一种MCR-1蛋白双抗夹心ELISA检测法，采用以下步骤：（1）以pH为9.5的Na2CO3溶液包被捕获抗体4E5(2 ng/mL)，酶标板中每孔加入100 μL，4℃过夜，使其与酶标板紧密结合；（2）次日，弃去孔内溶液，用洗涤液(PBST) 洗板3次，每次3 min；每孔加入100 μL2%BSA进行封闭，37℃温育2 h；封闭结束后向酶标板孔内加入细菌裂解液液，并同时设置阴性对照孔（0.01M PB，pH 7.4）和阳性对照孔（MCR-1蛋白，4 ng/mL），100 μL/孔，37℃孵育1h；（3）接着加入检测抗体5B3-HRP，100 μL/孔，37℃孵育1 h；（4）最后加入的显色剂TMB溶液（现用现配），每孔100 μL，37℃孵育10 min。在HRP作用下，显色剂发生颜色变化，加入终止液50 μL/孔；（5）测定：用酶标仪检测OD450nm。
在一个实施方案中，所述试剂盒中还包括终止液、封闭液和洗涤液；
具体的所述终止液为3 mol/L硫酸铵；
所述封闭液为2% BSA；
所述洗涤液为含0.1% Tween-20的0.01 M pH 7.4 PBST溶液。
本发明的有益效果是：本发明制备了MCR-1单克隆抗体并建立了双抗夹心ELISA方法，该方法检测MCR-1蛋白LOD为0.5ng/mL，与大肠杆菌、肺炎克雷伯氏菌、志贺菌、鼠伤寒沙门氏菌无交叉，说明具有良好的特异性，为试剂盒方法开发提供了科学依据。
附图说明
图1 MCR-1蛋白双抗体夹心ELISA标准曲线；
横坐标为不同稀释浓度的MCR-1蛋白标准品，纵坐标为相应的OD450nm吸光值。
图2 MCR-1与其他菌属的交叉反应。
具体实施方案
为了使本发明的目的和技术方案更加清楚，下面对本发明的优选实施案例进行详细描述。
1.MCR-1耐药蛋白的双抗夹心ELISA检测试剂盒的组成
本发明的双抗夹心ELISA 试剂盒包括包被有单克隆抗体4E5的酶标板、检测抗体5B3-HRP、MCR-1蛋白标准品、包被缓冲液、检测抗体稀释液、检测抗体工作液、样本稀释液、底物A液、底物B液、显色液、终止液、封闭液、洗涤液。
2.MCR-1耐药蛋白的双抗夹心ELISA检测试剂盒的制备
1）制备MCR-1蛋白
A、MCR-1基因的合成
从Genebank中获取MCR-1基因的氨基酸序列（Accession：WP 049589868.1），委托南京金斯瑞生物科技有限公司合成优化后的基因序列。
B、载体的构建
通过PCR扩增目的片段并克隆至表达载体pET28a，PCR反应扩增条件：95℃预变性5分钟；然后95℃变性40秒，58℃退火30秒，72℃延伸40秒，共进行25个循环；72℃延伸50秒。
C、MCR-1重组蛋白的表达与纯化
构建完成的重组质粒转入感受态细胞转化入大肠杆菌BL21(DE3)宿主菌株中，挑取单菌落接种至含有50 μg/mL卡那霉素的LB培养基中，37℃，200rpm培养至OD600达到0.6~0.8时，加入终浓度为0.5mM的IPTG，25℃条件下进行诱导表达。
4℃条件下，3200 g离心15 min收集菌体；然后使用20 mM Tris-HCl（含150mMNaCl）重悬菌体，3000 W，10 s/10s，15 min超声裂解菌体。采用Ni-NTA镍柱纯化系统纯化表达的MCR-1重组蛋白，用来制备鼠单克隆抗体。
测序结果：重组MCR-1蛋白时所用氨基酸序列如序列表中的序列1所示。
2）MCR-1单克隆抗体的制备
A、免疫实验动物
取步骤2制备的免疫原（重组MCR-1蛋白）溶液，将免疫原用无菌生理盐水稀释至1 mg/mL，首次免疫加入等量的弗氏完全佐剂，完全乳化后，采用颈背部皮下、多点注射的方式免疫8只小鼠，，免疫剂量为100 μg/只。共免疫6次，每次免疫间隔时间均为2周，具体免疫程序见表1。
表1. 单克隆抗体（小鼠）的免疫程序
B、抗血清的筛选
四免一周后，对小鼠眼眶采血，室温放置2 h，4000 rpm离心10 min后取血清检测；抗血清筛选先采用间接ELISA方阵滴定法确定包被原、抗体的最佳工作浓度，再采用间接竞争ELISA方法检测抗体的特异性和灵敏度。
C、杂交瘤细胞株的融合与筛选
按照常规方法进行，取免疫小鼠的脾细胞与处于对数生长期的小鼠骨髓瘤细胞(SP2/0)混合，然后用50% PEG进行免疫融合，用HAT培养基悬浮均匀，再加入适量的饲养细胞，培养于96孔培养板，于37℃，5% CO2培养箱中培养，5天后用HAT培养基半换液，9天时候进行全换液。
细胞融合后，待细胞长到培养孔面积的1/4时，吸出杂交瘤细胞上清液，并采用重组MCR-1蛋白包被酶标板及间接竞争ELISA方法筛选阳性、效价高的培养孔，得到的阳性孔用中国农业大学提供的MCR-1阳性大肠杆菌、肺炎克雷伯氏菌、志贺菌、鼠伤寒沙门氏菌裂解液包被的酶标板检测细胞的交叉反应，挑选所有MCR-1阳性菌株均有反应的强阳性孔进行性亚克隆。其中MCR-1阳性菌的鉴定方法参照：Liu Y Y , et al. Emergence ofplasmid-mediated colistin resistance mechanism MCR-1 in animals and humanbeings in China: a microbiological and molecular biological study[J]. LancetInfectious Diseases, 2016, 16:161-168.
将数次亚克隆建株后的杂交瘤细胞扩大培养，收集上清液用间接ELISA测定效价，冻存；并取8-10周龄Balb/c小鼠腹腔注射0.3 mL/只含1.3x106个细胞的细胞悬液。6天后观察小鼠，当小鼠腹部膨大时，抽取腹水，每隔2天观察小鼠，及时抽取腹水；将抽取的腹水10000r/min离心5 min，收集上清，分装保存于-20℃冰箱。
D、腹水中抗体的纯化
将5 mL腹水在10000 r/min、4℃条件下离心5 min，收集上清液，然后加入20 mL倍体的0.06 mM醋酸钠缓冲液（pH 4.0）进行稀释，再使用0.2 M NaOH调节pH至4.5左右；加入1000μL正辛酸缓慢加入正辛酸并搅拌30 min，4℃静置1 h；将上述液体在6000 r/min、4℃条件下离心30 min，收集上清并过滤；加入2.6 mL 的PBS缓冲液进行稀释（加入的量应为上述滤液的10 %）；加入等体积的饱和硫酸铵，并搅拌30 min，4℃静置1 h；弃上清，加入适量PBS缓冲液重悬后装入透析袋，置于0.02 mM PBS缓冲液中与4℃透析24-48 h并适时换液，收集透析袋内液体，-20℃保存，得到单克隆抗体。
测序结果：本发明4E5单克隆抗体的重链和轻链可变区的氨基酸序列分别如序列表中序列2和序列3所示；5B3单克隆抗体的重链和轻链可变区的氨基酸序列分别如序列表中序列4和序列5所示。
E、经辣根过氧化物酶标记的MCR-1检测抗体的制备方法：
（1）称取5 mg HRP（辣根过氧化物酶，购自Sigma）溶于1 mL三蒸水中，逐滴缓慢加入0.20 mL新配的0.1 M NaIO4溶液，4℃避光搅拌25 min，活化HRP，颜色由棕色变为绿色。上述溶液装入透析袋中，用1 M pH为4.4的醋酸钠缓冲液透析，4℃过夜。10000 r/min，4℃，10min，离心去除沉淀。得到透析后的HRP。
（2）将5B3检测抗体用0.2M，pH为9.5的碳酸缓冲液4℃透析过夜。观察是否有沉淀，并分析沉淀性状，10000 r/min，4℃，10 min，离心去除沉淀，得到透析后的抗体。
（3）将透析后的HRP加入0.16 M乙二醇（每mg酶加0.1 mL），4℃避光搅拌1 h，然后加入透析后的抗体；两者混匀后用0.05 M，pH为9.5的碳酸缓冲液4℃透析过夜，得到HRP-抗体混合液；
（4）将上述溶液装入透析袋中，对0.15 M pH 7.4 PBS透析过夜。搅拌下逐滴加入等体积饱和硫酸氨，4℃避光搅拌3 h。4℃，10000 rpm离心15 min，弃上清。PBS溶解沉淀，得到经辣根过氧化物酶标记的5B3-HRP检测抗体。
F、包被有4E5单克隆抗体的酶标板的制备
将4E5单克隆抗体用碳酸盐缓冲液稀释成浓度为5 μg/mL的抗体包被液，每孔100 μL，4℃包被过夜后洗板；然后每孔加入100 μL封闭液，37℃、湿度30-40%封闭2 h，37℃、湿度30-40%恒温干燥2 h。
3. MCR-1双抗夹心Elisa检测方法建立
A、双抗体夹心ELISA检测法测定步骤
（1）以pH为9.5的碳酸盐缓冲液包被捕获抗体4E5 (3 ng/mL)，在96孔酶标板中每孔加入100 μL，4℃包被过夜，使其与酶标板紧密结合；
（2）次日，弃去孔内溶液，用洗涤液 (PBST) 洗板3次，每次3min。每孔再加100 μL的2%牛血清蛋白作为封闭液，37℃温育2 h。封闭结束后，弃去孔内溶液，洗板3次，在酶标板孔内加入待测蛋白提取物溶液(以待测样品与PBS缓冲液的体积比为稀释倍数)和MCR-1蛋白(每孔5 ng/mL)，100 μL/孔，37℃孵育1 h；
（3）接着加入检测抗体5B3-HRP，100 μL/孔，37℃孵育1 h；
（4）最后在形成的复合物中加入临时配制的显色剂TMB溶液，每孔100 μL，37℃孵育10～30 min。在HRP作用下，显色剂发生颜色变化，加入终止液50 μL/孔；
（5）测定：用酶标仪检测OD450nm。
B、方法的建立
（1）MCR-1蛋白的线性范围
以MCR-1蛋白标准品作系列稀释至0.5~16 ng/mL，用上述建立的双抗体夹心ELISA方法进行检测，进行3次重复，以MCR-1蛋白标准品质量浓度(ng/mL)为横坐标，OD450值为纵坐标制作标准曲线，用origin8.0 (OriginLab Corp, Northampton, MA, USA) 软件中的四参数拟合竞争标准曲线，确定线性范围与检测限LOD（LOD是空白的平均吸收值加3倍的空白吸收值的标准偏差对应的抗原浓度）。
（2） 特异性验证
以最佳配对的抗体以及最佳浓度来进行双抗体夹心ELISA检测特异性，分别用MCR-1阳性的大肠杆菌、肺炎克雷伯氏菌、志贺菌、鼠伤寒沙门氏菌，以及大肠杆菌ATCC 25922，大肠杆菌ATCC35150，肺炎克雷伯氏菌ATCC 10031，志贺菌CICC 21534，鼠伤寒沙门氏菌ATCC13311进行特异性检测。
4.结果
1）ELISA检测方法建立
（1）标准曲线
通过测试数据拟合曲线表明（图1），本方法对MCR-1，检出限为0.5 ng/mL，R2=0.997，方程为Y=2.419+(0.23-2.419)/(1+(x/1.066)1.7)。
（2）特异性的检测
以最佳配对的抗体以及最佳浓度来进行双抗体夹心ELISA检测特异性．其分别与带有MCR-1阳性的大肠杆菌、肺炎克雷伯氏菌、志贺菌、鼠伤寒沙门氏菌（图2）。结果表明，与MCR-1阳性的大肠杆菌、肺炎克雷伯氏菌、志贺菌、鼠伤寒沙门氏菌进行特异性检测均有交叉反应，与标准菌株大肠杆菌ATCC 25922，大肠杆菌ATCC 35150，肺炎克雷伯氏菌ATCC 10031，志贺菌CICC 21534，鼠伤寒沙门氏菌ATCC 13311无交叉反应，说明特异性良好。
序列表
<110> 北京维德维康生物技术有限公司
<120> MCR-1耐药蛋白双抗夹心ELISA检测试剂盒及检测方法
<141> 2020-06-15
<150> 2020101803879
<151> 2020-03-16
<160> 5
<170> SIPOSequenceListing 1.0
<210> 1
<211> 379
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 1
aactcgttaa cgcggacgag tatattggct tagtggtagg gaattcctat gggagagtct 60
tgttgtgtgt tatatgatgg taaaagggcg aggggtttgg gaaaggacag gaccctacag 120
cgactgtatc gggactggac aggttcagga gatggaagag ggggtaaagc gctgtagtag 180
gggttctgtc cgtctatcgc actgagtggg tagttggtga ggctagttcg cgggagggaa 240
gtgcatttac tttttcaggg agggggaatt gggaacagtc gatgatggag tgcgtagccc 300
tatgtaatgg acttcctatg gcatgcgcgc gtggtcgata agacgattgg tgtaatgtgt 360
cgattgggta gggggataa 379
<210> 2
<211> 121
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 2
Gln Val Gln Leu Gln Gln Ser Arg Ala Glu Leu Val Lys Pro Gly Ala
1 5 10 15
Ser Glu Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45
Gly Glu Ile Asn Pro Ser Asn Gly Arg Thr Asn Tyr Asn Glu Asn Phe
50 55 60
Lys Ser Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Ser Ala Tyr
65 70 75 80
Met Ser Glu Ser Leu Thr Gln Leu Ser Asp Ser Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Glu Asp Leu Tyr Asp Gln His Tyr Tyr Trp Gly Gln Gly
100 105 110
Thr Ala Thr Ser Val Thr Val Ser Ser
115 120
<210> 3
<211> 111
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 3
Asp Ile Leu Leu Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly
1 5 10 15
Asp Gln Ala Ser Ile Ser Cys Arg Ser Leu Pro Ser Gln Val His Arg
20 25 30
Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Glu Pro Gly Gln Ser
35 40 45
Pro Ile Arg Asn Lys Leu Lys Val Ser Tyr Leu Phe Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg His Glu Ala Asp Val Tyr Phe Cys Leu Gly Tyr Leu Ser Ala
85 90 95
Val Pro Tyr Thr Phe Ser Gly Gly Thr Lys Leu Glu Ile Lys Arg
100 105 110
<210> 4
<211> 118
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 4
Glu Gln Leu Gln Val Gln Gln Ser Arg Ala Leu Val Lys Pro Gly Ala
1 5 10 15
Ser Glu Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45
Gly Glu Ile Asn Pro Ser Arg Gly Asn Thr Asn Tyr Asn Glu Asn Phe
50 55 60
Lys Ser Lys Ala Thr Leu Thr Val Asp Lys Glu Ser Thr Ser Ser Ala
65 70 75 80
Leu Tyr Met Gln Leu Ser Ser Ser Ser Asp Ser Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Tyr Asp Asp Tyr Ser Leu Tyr His Glu Asp Trp Gly Gln Gly
100 105 110
Thr Ser Val Thr Val Ser
115
<210> 5
<211> 112
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 5
Ile Asp Leu Leu Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly
1 5 10 15
Asp Gln Ala Ser Cys Arg Ser Ser Gln Ser Leu Val His Arg Ile Ser
20 25 30
Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Glu Pro Gly Gln Ser
35 40 45
Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser Ala
85 90 95
His Val Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Lys Arg Ile
100 105 110
Claims (10)
1.一种用于检测细菌中MCR-1耐药蛋白的双抗夹心ELISA检测试剂盒，包括：包被有单克隆抗体4E5的酶标板、检测抗体5B3-HRP、MCR-1蛋白标准品。
2.根据权利要求1所述的检测MCR-1耐药蛋白的双抗夹心ELISA检测试剂盒，其特征在于：
所述单克隆抗体4E5和检测抗体5B3为采用重组MCR-1蛋白蛋白免疫小鼠，经融合、克隆、筛选，得到的。
3.根据权利要求1或2所述的检测MCR-1耐药蛋白的双抗夹心ELISA检测试剂盒，其特征在于：
所述单克隆抗体4E5的重链可变区的氨基酸序列为序列2；
所述单克隆抗体4E5的轻链可变区的氨基酸序列为序列3；
所述单克隆抗体5B3的重链可变区的氨基酸序列为序列4；
所述单克隆抗体5B3的轻链可变区的氨基酸序列为序列5。
4.根据权利要求2所述的检测MCR-1耐药蛋白的双抗夹心ELISA检测试剂盒，其特征在于：
PCR扩增目的片段并克隆至表达载体pET28a，将成功构建的重组表达质粒转化至大肠杆菌BL21（DE3）中，IPTG诱导表达，经亲和层析和分子筛层析高度纯化后得到MCR-1重组蛋白。
5.根据权利要求4所述的检测MCR-1耐药蛋白的双抗夹心ELISA检测试剂盒，其特征在于，重组MCR-1蛋白氨基酸序列为序列1。
6.根据权利要求1所述的检测MCR-1耐药蛋白的双抗夹心ELISA检测试剂盒，其特征在于，所述检测抗体5B3-HRP的制备方法步骤包括：
（1）称取5 mg HRP溶于1 mL三蒸水中，逐滴缓慢加入0.20 mL新配的0.1 M NaIO4溶液，4℃避光搅拌25 min，活化HRP，颜色由棕色变为绿色；上述溶液装入透析袋中，用1 M，pH为4.4的醋酸钠缓冲液中4℃过夜透析，然后10000 r/min，4℃，离心10 min，去除沉淀；得到透析后的HRP；
（2）将单克隆抗体5B3用0.2 M，pH为9.5的碳酸缓冲液4℃透析过夜，得到透析后的抗体；
（3）将透析后的HRP加入0.16 M乙二醇（每mg酶加0.1 mL），4℃避光搅拌1 h，然后加入透析后的抗体；两者混匀后用0.05 M，pH为9.5的碳酸缓冲液4℃透析过夜，得到HRP-抗体混合液；
（4）对0.15 M pH 7.4 PBS透析过夜；搅拌下逐滴加入等体积饱和硫酸氨，4℃避光搅拌3 h；4℃，10000 rpm离心15 min，弃上清；PBS溶解沉淀，得到经辣根过氧化物酶标记的检测抗体5B3-HRP，使用酶标记物稀释液1:30000倍稀释后备用。
7.一种制备权利要求1-6中任一所述的试剂盒的方法，包括如下步骤：
1）包被有单克隆抗体4E5的酶标板的制备：将单克隆抗体4E5用碳酸盐缓冲液稀释成浓度为5 μg/mL的抗体包被液，每孔100 μL，4℃包被过夜后洗板；然后每孔加入100 μL封闭液，37℃、湿度30-40%封闭2 h，37℃、湿度30-40%恒温干燥2 h；
2）检测抗体稀释液：0.01 M pH7.4的PBST溶液；
3）检测抗体工作液的制备：检测抗体5B3-HRP按照 1:30000比例稀释后备用；
4）样品稀释液的制备：0.01 M pH7.4的PBS溶液；
5）底物A液的制备：含0.08%过氧化脲、0.025%PEG-2000、3.58%十二水合磷酸氢二钠、0.96%一水合柠檬酸水溶液，调pH值至7.4；
6）底物B液的制备：含1.03%一水合柠檬酸、0.04% TMB、0.0008%硫代硫酸钠、0.1%光稳定剂292、3% DMF水溶液，调pH值至5.0。
8.一种用于检测MCR-1耐药蛋白的双抗夹心ELISA检测法，其特征在于：
（1）向包被有单克隆抗体4E5的酶标板中加入细菌菌体裂解液和MCR-1蛋白稀释液，100μL/孔，37℃孵育1 h；
（2）用PBST洗涤三次，每次3 min，200 μL/孔，然后甩干反应板；
（3）接着加入检测抗体5B3-HRP，100 μL/孔，37℃孵育1h；
（4）用PBST洗涤三次，每次3 min，200 μL/孔，然后甩干反应板；
（5）最后在形成的复合物中加入临时配制的显色剂TMB溶液，每孔100 μL，37℃孵育10～30 min，在HRP作用下，显色剂发生颜色变化，加入终止液50 μL/孔；
（6）测定：用酶标仪检测OD450nm。
9.根据权利要求1所述的试剂盒或权利要求8所述的方法，其特征在于，所述试剂盒中还包括终止液、封闭液和洗涤液；
具体的所述终止液为3 mol/L硫酸铵；
所述封闭液为2% BSA；
所述洗涤液为含0.1% Tween-20的0.01 M pH 7.4 PBST溶液。
10.根据权利要求8所述的方法，其特征在于，所述细菌菌体裂解液的制备方法为：
4℃条件下，3500 g离心15 min收集菌体，然后使用20 mM Tris-HCl（含150 mM NaCl）重悬菌体，通过超声裂解菌体，超声条件为3000 W，10 s/10s，15 min。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020101803879 | 2020-03-16 | ||
| CN202010180387 | 2020-03-16 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111487417A true CN111487417A (zh) | 2020-08-04 |
| CN111487417B CN111487417B (zh) | 2024-01-23 |
Family
ID=71795763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010542174.6A Active CN111487417B (zh) | 2020-03-16 | 2020-06-15 | Mcr-1耐药蛋白双抗夹心elisa检测试剂盒及检测方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111487417B (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113416710A (zh) * | 2021-08-25 | 2021-09-21 | 天津一瑞生物科技股份有限公司 | 一种鼠抗mcr-1蛋白杂交瘤细胞株，单克隆抗体及应用 |
| CN114317455A (zh) * | 2022-03-02 | 2022-04-12 | 天津一瑞生物科技股份有限公司 | 鼠抗mcr-1蛋白杂交瘤细胞株，单克隆抗体及应用 |
| EP4265717A4 (en) * | 2022-03-01 | 2024-04-17 | Tianjin Era Biology Technology Co., Ltd. | MOUSE ANTI-MCR-1/MCR-2 PROTEIN HYBRIDOMA CELL STRAIN, MONOCLONAL ANTIBODY AND USE |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6117981A (en) * | 1999-06-03 | 2000-09-12 | Cytoclonal Pharmaceutics, Inc. | Hybridomas for lung cancer marker and monoclonal antibodies thereof |
| CN106885908A (zh) * | 2015-12-23 | 2017-06-23 | 中国人民解放军第二军医大学 | 血清psmd4蛋白的检测试剂盒及其检测方法与应用 |
| CN107022029A (zh) * | 2017-03-23 | 2017-08-08 | 暨南大学 | 高特异高灵敏检测甲胎蛋白的单克隆抗体及试剂盒和应用 |
| CN107099506A (zh) * | 2017-04-24 | 2017-08-29 | 江苏省农业科学院 | 猪流行性腹泻病毒双抗体夹心elisa定量检测试剂盒及其应用 |
| CN109507435A (zh) * | 2018-11-23 | 2019-03-22 | 重庆医科大学 | Grp78蛋白双抗夹心elisa法检测试剂盒及其检测方法 |
-
2020
- 2020-06-15 CN CN202010542174.6A patent/CN111487417B/zh active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6117981A (en) * | 1999-06-03 | 2000-09-12 | Cytoclonal Pharmaceutics, Inc. | Hybridomas for lung cancer marker and monoclonal antibodies thereof |
| CN106885908A (zh) * | 2015-12-23 | 2017-06-23 | 中国人民解放军第二军医大学 | 血清psmd4蛋白的检测试剂盒及其检测方法与应用 |
| CN107022029A (zh) * | 2017-03-23 | 2017-08-08 | 暨南大学 | 高特异高灵敏检测甲胎蛋白的单克隆抗体及试剂盒和应用 |
| CN107099506A (zh) * | 2017-04-24 | 2017-08-29 | 江苏省农业科学院 | 猪流行性腹泻病毒双抗体夹心elisa定量检测试剂盒及其应用 |
| CN109507435A (zh) * | 2018-11-23 | 2019-03-22 | 重庆医科大学 | Grp78蛋白双抗夹心elisa法检测试剂盒及其检测方法 |
Non-Patent Citations (2)
| Title |
|---|
| XIAOHUA HE 等: "1-10", SCIENTIFIC REPORTS * |
| 石曼等: "检测乳粉中克罗诺杆菌属穆汀斯克罗诺杆菌的双抗夹心ELISA方法的研究", 分析检测 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113416710A (zh) * | 2021-08-25 | 2021-09-21 | 天津一瑞生物科技股份有限公司 | 一种鼠抗mcr-1蛋白杂交瘤细胞株，单克隆抗体及应用 |
| CN113416710B (zh) * | 2021-08-25 | 2021-12-17 | 天津一瑞生物科技股份有限公司 | 一种鼠抗mcr-1蛋白杂交瘤细胞株，单克隆抗体及应用 |
| WO2023024313A1 (zh) * | 2021-08-25 | 2023-03-02 | 天津一瑞生物科技股份有限公司 | 一种鼠抗mcr-1蛋白杂交瘤细胞株，单克隆抗体及应用 |
| EP4265717A4 (en) * | 2022-03-01 | 2024-04-17 | Tianjin Era Biology Technology Co., Ltd. | MOUSE ANTI-MCR-1/MCR-2 PROTEIN HYBRIDOMA CELL STRAIN, MONOCLONAL ANTIBODY AND USE |
| CN114317455A (zh) * | 2022-03-02 | 2022-04-12 | 天津一瑞生物科技股份有限公司 | 鼠抗mcr-1蛋白杂交瘤细胞株，单克隆抗体及应用 |
| CN114317455B (zh) * | 2022-03-02 | 2022-05-31 | 天津一瑞生物科技股份有限公司 | 鼠抗mcr-1蛋白杂交瘤细胞株，单克隆抗体及应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111487417B (zh) | 2024-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111487417A (zh) | Mcr-1耐药蛋白双抗夹心elisa检测试剂盒及检测方法 | |
| CN101942416B (zh) | 抗人心肌肌钙蛋白i特异性单克隆抗体及其制备方法 | |
| CN111269318B (zh) | 一种gapdh纳米抗体及其应用 | |
| CN113527476B (zh) | 抗h5亚型禽流感病毒新纳米抗体及其应用 | |
| CN105198990B (zh) | 用于Bt Cry1类毒素广谱检测的抗体及其制备方法与应用 | |
| CN111487418B (zh) | Ndm-1耐药蛋白双抗夹心elisa检测试剂盒及检测方法 | |
| CN111521778A (zh) | 一种检测ndm-1耐药蛋白双抗夹心elisa试剂盒及检测方法 | |
| CN102911919A (zh) | 一种bar/PAT蛋白单克隆抗体及其制备方法和应用 | |
| CN108034637B (zh) | Gr79-epsps的单克隆抗体试纸条及其应用 | |
| AU2020101140A4 (en) | ELISA kit for quantitative detection of content of insect cadherin and use method thereof | |
| CN111487416B (zh) | optrA耐药蛋白双抗夹心ELISA检测试剂盒及检测方法 | |
| CN110261606B (zh) | 一种产气荚膜梭菌β毒素抗体捕获ELISA检测方法 | |
| CN103848916B (zh) | 一种抗cp4 epsps单克隆抗体的制备方法、编码序列及其应用 | |
| CN116589567B (zh) | 马铃薯x病毒单克隆抗体pvx-2及其应用 | |
| CN105158475B (zh) | 用于检测转基因农作物的单克隆抗体对及双抗夹心酶联免疫检测试剂盒 | |
| CN103361741A (zh) | 一种噬菌体抗体库及其在盐酸克伦特罗含量测定中的应用 | |
| CN114164181B (zh) | 一种产生牛妊娠相关糖蛋白pag8单克隆抗体的杂交瘤细胞株及其应用 | |
| CN114280306A (zh) | 牛筋草epsps蛋白elisa检测试剂盒及检测方法 | |
| CN116535500A (zh) | 马铃薯x病毒单克隆抗体pvx-6及其应用 | |
| CN102181402B (zh) | 高致病性猪繁殖与呼吸综合征病毒单克隆抗体及其制备 | |
| CN116338193A (zh) | 一种基于抗体捕获的非洲马瘟间接elisa抗体检测试剂盒及其应用 | |
| CN108047330B (zh) | Cry2Ah1蛋白的单克隆抗体 | |
| CN108414768B (zh) | 一种抗草甘膦gat转基因农作物的金标检测试纸条 | |
| CN109030830B (zh) | 黏附素蛋白Apd及其在制备副猪嗜血杆菌间接ELISA抗体检测试剂盒中的应用 | |
| CN112342198A (zh) | PAT/pat单抗杂交瘤细胞株、产生的抗体及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |